

RECEIVED
CENTRAL FAX CENTER

Attorney Docket No.: 5956.200-US

OCT 11 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al. Confirmation No.: 9106
Application No.: 09/662,457 Group Art Unit: 1626
Filed: September 11, 2000 Examiner: Saeed, Kamal A.
For: Modulators of Protein Tyrosine Phosphatases (PTPases)

CERTIFICATE OF FACSIMILE TRANSMISSION
Fax No.: 703-872-9306

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement
2. Petition for Extension of Time (one month, in duplicate)

is being deposited with the United States Patent and Trademark Office:
via facsimile number 703-872-9306 on October 11, 2004.

Rosemarie R. Wilk-Orescan, Esq.
(name of person mailing paper)


(signature of person mailing paper)

Application Number: 09/662,457
Andersen et al.
Filed: September 11, 2000
Attorney Docket No.: 5956.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al. Confirmation No.: 9106
Application No.: 09/662,457 Group Art Unit: 1626
Filed: September 11, 2000 Examiner: Saeed, Kamal A.
For: Modulators of Protein Tyrosine Phosphatases (PTPases)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being timely filed in response to the Office Action mailed August 12, 2004, having a shortened statutory period for reply set to expire September 12, 2004, subject to extensions of time under 37 C.F.R. §1.136(a). A petition for a one (1) month extension of time to increase the period for reply to October 12, 2004, is enclosed herewith to permit timely filing of this response.

The examiner states that claims numbered 110-221 are pending in the application and claims 110-221 are subject to restriction and/or election requirement. The examiner states restriction to one of the following inventions is required under 35 U.S.C. §121:


Group I. Claims 110-126, 128, 130, 132-134, 138, 140, 143, 150, 152, 154, 156-158, 162, 164, 167-169, 172, 173, 176, 177, 181, 186-202, 204, 206, 208-210, 214, 216 and 219-221: drawn to compounds of the formula (I).

Group II. Claims 127, 129, 131, 135-137, 139, 141, 151, 153, 155, 159-161, 163, 165, 171, 174, 175, 178-180, 182, 184, 203, 205, 207, 211-213, 215 and 217: drawn to methods of use for the compounds of the formula (I).

Group III. Claims, 142, 166, 185 and 218: drawn to a process of preparing compounds of formula (I).

In response to the restriction requirement, Applicant hereby elects, for examination purposes, the invention of Group I: Claims 110-126, 128, 130, 132-134, 138, 140, 143, 150, 152, 154, 156-158, 162, 164, 167-169, 172, 173, 176, 177, 181, 186-202, 204, 206, 208-210, 214, 216 and 219-221: drawn to compounds of the formula (I).

Applicant additionally elects a single species, for examination purposes, disclosed in Example 47, page 107, line 30 of the specification as originally filed:



2-(Oxalyl-amino)-7-(1,1,3-trioxo-1H-benzo[d]isothiazol-3-ylloxomethyl)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid.

Applicant hereby reserves the right to file continuing or divisional applications directed to the nonelected and/or cancelled subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Rosemarie R. Wilk-Orescan
Registration Number 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
609-987-5969

Date: October 11, 2004

Customer Number

23650

PATENT TRADEMARK OFFICE